No Patient or Illness to be Treated?:The Hazards of Investigations Carried Out nder Article 102 TFEU for Price-Related Conduct (The Netherlands, Case 7069, AstraZeneca)
This article discusses the decision of the netherlands competition authority in the AstraZeneca case and puts this in a broader perspective of regulation in the pharmaceutical market, price regulation and responses to market failures.
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2015 |
| Reihe/Periodikum: | Vedder , H 2015 , ' No Patient or Illness to be Treated? The Hazards of Investigations Carried Out nder Article 102 TFEU for Price-Related Conduct (The Netherlands, Case 7069, AstraZeneca) ' , Journal of European Competition Law & Practice , vol. 6 , no. 9 , pp. 664-668 . https://doi.org/10.1093/jeclap/lpv057 |
| Schlagwörter: | Pharmaceutical markets / competition law |
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-26825591 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | https://hdl.handle.net/11370/759bdcaf-1409-4943-bfee-4292e48101ba |
